GreenLight Biosciences (NASDAQ:GRNA) to be acquired by a group of buyers led by Fall Line Capital in an all-cash transaction valued at $45.5M.
Fall Line, together with its affiliates, agreed that it would commence a tender offer to acquire all shares for $0.30 per share, net to the seller in cash.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased